XENE Dec 2024 35.000 call
| Previous Close | 9.50 |
| Open | N/A |
| Bid | 14.10 |
| Ask | 16.50 |
| Strike | 35.00 |
| Expire Date | 2024-12-20 |
| Day's Range | 9.50 - 9.50 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 1 |
Simply Wall St.Shareholders Will Probably Not Have Any Issues With Xenon Pharmaceuticals Inc.'s (NASDAQ:XENE) CEO Compensation
Key Insights Xenon Pharmaceuticals to hold its Annual General Meeting on 4th of June Total pay for CEO Ian Mortimer...
GlobeNewswireXenon Pharmaceuticals Presents Data from Phase 2 X-NOVA Clinical Trial of Azetukalner in Major Depressive Disorder at the American Society of Clinical Psychopharmacology 2024 Annual Meeting
VANCOUVER, British Columbia, May 28, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neuroscience-focused biopharmaceutical company, announced data presentations highlighting azetukalner (XEN1101) clinical data in major depressive disorder (MDD) at the American Society of Clinical Psychopharmacology (ASCP) 2024 Annual Meeting in Miami, FL. Mr. Ian Mortimer, Xenon’s President and Chief Executive Officer, stated, “We are pleased to present these data from our Phase 2 proof-of-
Insider MonkeyHedge Funds are Racking Up Shares of This Healthcare Stock
We recently compiled a list of the 7 Best Mid-Cap Healthcare Stocks To Buy Now and in this article we will look at whether hedge funds like Xenon Pharmaceuticals Inc. (NASDAQ:XENE). Challenges in the Health Sector The healthcare industry is considered to be a fairly defensive sector due to its need. According to a World […]
